Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on November 30, 2022. Three individuals hired by Adicet in November 2022 received, in the aggregate, non-qualified stock...
